LRRK2 and Platelet storage pool disease: To further prove the involvement of E. coli drived-intestinal microbiota dysbiosis in LRRK2-associated sPD pathogenesis and to evaluate the potential protective effects of FMT treatment on E. coli-treated Lrrk2 R1628P mice, we transplanted the fecal microbiota from healthy donor mice (WT mice, 12 weeks of age) into a random sample of Lrrk2RP/+E. coli and Lrrk2RP/RPE. coli mice at 15 wpfg and 12 wpfg (Lrrk2RP/+E. coli-FMT and Lrrk2RP/RPE. coli-FMT), respectively.